Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: A retrospective analysis of prospectively recruited patients

Strahlentherapie und Onkologie

Volumn 182, Issue 4, 2006, Pages 210-215

  Brunner, Thomas B ^a   Tinkl, Dominik ^a   Grabenbauer, Gerhard G ^a   Meyer, Thomas ^a   Brueckl, Wolfgang M ^a   Sauer, Rolf ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Additive; Chemoradiation; Chemotherapy; Gemcitabine; Pancreatic carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; MITOMYCIN C;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DERMATITIS; DUODENUM BLEEDING; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; LYMPHATIC SYSTEM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CARCINOMA; PHYSICIAN; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ALGORITHMS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; DATA INTERPRETATION, STATISTICAL; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 33645852580     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-006-1524-x     Document Type: Article

References (37)

1. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002;20:3270-5.
2. Brunner TB, Grabenbauer GG, Kastl S, et al. Preoperative chemoradiation in locally advanced pancreatic carcinoma: a phase II study. Onkologie 2000;23:436-42.
3. Brunner TB, Hahn SM, McKenna WG, et al. Radiation sensitization by inhibition of activated Ras. Strahlenther Onkol 2004;180:731-40.
4. Brunner TB, Merkel S, Grabenbauer GG, et al. Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based upon histopathologic analysis. Int J Radiat Oncol Biol Phys 2005;62:1021-9.
5. Brunner TB, Schwab D, Meyer T, et al. Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma. A retrospective analysis. Strahlenther Onkol 2004;180:751-7.
6. Burn's HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
7. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002;94:902-10.
8. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6.
9. Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002;52:1293-302.
10. Crane CH, Janjan NA, Evans DB, et al. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 2001;29:9-18.
11. GITSG. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 1987;59:2006-10.
12. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). J Clin Oncol 2005;23:1092s.abstract LBA 4010.
13. Huguet F, André T, Hammel P, et al. Chemoradiotherapy (CRT) after chemotherapy (CT) improves survival for locally-advanced (LA) pancreatic cancer patients: retrospective analysis of 181 patients enrolled in prospective phases II and III GERCOR studies. J Clin Oncol 2005;23:331s. abstract 4095.
14. Ishii H, Okada S, Tokuuye K, et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997;79:1516-20.
15. Johnson CD, Puntis M, Davidson N, et al. Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma. Br J Surg 2001;88:662-8.
16. Kachnic LA, Shaw JE, Manning MA, et al. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. Int J Cancer 2001;96:132-9.
17. Klautke G, Foitzik T, Ludwig K, et al. Neoadjuvant radiochemotherapy in locally advanced gastric carcinoma. Strahlenther Onkol 2004;180:695-700.
18. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999;230:776-82.
19. Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol 1997;168:1439-43.
20. Maisey N, Chau I, Cunningham D, et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002;20:3130-6.
21. McGinn CJ, Lawrence TS, Zalupski MM. On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer. Cancer 2002;95:933-40.
22. McGinn CJ, Zalupski MM. Combined-modality therapy in pancreatic cancer: current status and future directions. Cancer J 2002;7:338-48.
23. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19:4202-8.
24. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981;48:1705-10.
25. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol 2005;23:1s.abstract 1.
26. National Cancer Institute. Annual cancer statistics review 1973-1988. NIH Publication No. 91-2789. Bethesda: NIH, 1991.
27. Neuhaus P, Oettle H, Post S, et al. A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. J Clin Oncol 2005;23:1029s. abstract LBA 4013.
28. Oettle H, Pelzer U, Stieler J, et al. Oxaliplatin/folinic acid/5-fluorouracil [24 h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol 2005;23:315s.abstract 4031.
29. Okusaka T, Ito Y, Ueno H, et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 2004;91:673-7.
30. Rich TA. Chemoradiation for pancreatic and biliary cancer: current status of RTOG studies. Ann Oncol 1999;10:Suppl 4:231-3.
31. Riess H, Helm A, Niedergethmann M, et al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 2005;23: 1092s.abstract LBA 4009.
32. Rubin P, Constine LS, Fajardo LF, et al. RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. Int J Radiat Oncol Biol Phys 1995;31:1041-2.
33. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
34. Shinchi H, Takao S, Noma H, et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002;53:146-50.
35. Wenz F, Tiefenbacher U, Fuss M, et al. Should patients with locally advanced, non-metastatic carcinoma of the pancreas be irradiated? Pancreatology 2003;3:359-65.
36. Wilkowski R, Thoma M, Heinemann V, et al. Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer - feasible and effective. Strahlenther Onkol 2003;179:78-86.
37. Wulf J, Kramer K, van Aaken C, et al. Outcome of postoperative treatment for rectal cancer UICC stage II and III in day-to-day clinical practice. Results from a retrospective quality control analysis in six institutions in North Bavaria (Germany). Strahlenther Onkol 2004;180:5-14.